19 Organizations Will Receive a Total of $12.6 Million in Grant Funding Through Gilead’s Setting the P.A.C.E. Initiative FOSTER CITY, CA – Gilead Sciences, Inc. (Nasdaq: GILD) announced it is… Read More
A supplementary Biologics License Application (sBLA) is supported by data from the Phase 1/2 EPCORE™ NHL-1 clinical trial in patients with relapsed or refractory (R/R) follicular lymphoma (FL), demonstrating strong… Read More
RESEARCH TRIANGLE PARK, NC – IQVIA™ (NYSE:IQV), has published its 2023 Environmental, Social and Governance (ESG) Report. The annual report provides a detailed account of the organization’s focus on reducing… Read More
Submission supported by positive results of a Phase III study showing immune response and tolerability in adults aged 50-59 Adults aged 50 and above with underlying medical conditions are at… Read More
Biktarvy Now First and Only INSTI-Based Single-Tablet Regimen That is FDA Approved and DHHS Guideline Recommended for People Who are Virologically Suppressed with M184V/I Resistance M184V/I One of the Most… Read More
